Trial Profile
A Retrospective, cohort study to evaluate the efficacy associated with RSV-related hospitalizations in preterm infants of 28 weeks of GA treated with Palivizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 09 Jun 2017 New trial record